Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 8/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 2/20 | 0.61 |
| ▸ | BACE1 | P56817 | 2/20 | 0.61 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.61 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.61 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22291036 | 0.91 | ENPP1 (0.72) | ENPP1MAPK1ACHEBACE1SIRT2 | |
| SCHEMBL24391804 | 0.89 | ACHE (0.57) | ENPP1MAPK1ACHEBACE1AURKA | |
| SCHEMBL29588669 | 0.89 | ACHE (0.57) | ENPP1MAPK1ACHEBACE1AURKA | |
| SCHEMBL22455025 | 0.88 | ENPP1 (0.66) | ENPP1MAPK1ACHEBACE1SIRT2 | |
| SCHEMBL20782515 | 0.86 | ENPP1 (0.75) | ENPP1MAPK1ACHEBACE1SIRT2 | |
| SCHEMBL7274375 | 0.86 | ENPP1 (0.65) | ENPP1MAPK1ACHEBACE1AURKA | |
| SCHEMBL21358424 | 0.84 | ENPP1 (0.71) | ENPP1MAPK1ACHEBACE1PDE10A | |
| SCHEMBL29354481 | 0.84 | ENPP1 (0.71) | ENPP1MAPK1ACHEBACE1PDE10A | |
| SCHEMBL7285219 | 0.84 | ENPP1 (0.61) | ENPP1MAPK1ACHEBACE1AURKA | |
| SCHEMBL10800770 | 0.84 | ENPP1 (0.61) | ENPP1MAPK1ACHEBACE1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | ENPP1 1/4885MAPK1 2004/4885ACHE 2363/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | ENPP1 1/4885MAPK1 2004/4885ACHE 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.